Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses

Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses Publisher Pubmed

Savoji MA^{1, 2} ; Sereshgi MMA^{3, 4} ; Ghahari SMM¹ ; Asgarhalvaei F^{1, 2} ; Mahdavi M^{1, 5, 6}

Show Affiliations

1. Recombinant Vaccine Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Microbiology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
3. Department of Immunology, Shahed University, Tehran, Iran
4. Immunoregulation Research Center, Shahed University, Tehran, Iran
5. Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
6. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran

Source: International Immunopharmacology Published:2021

Abstract

Montanide ISA 51VG adjuvant has been approved for human clinical application and stimulates cellular and humoral immune responses. Here, HBsAg was formulated in Montanide ISA51VG adjuvant to compare its potency with the Fendrix and HBsAg-alum vaccines. In particular, the long-term humoral response was assessed up to 220 days after the final immunization. BALB/c mice were allocated into six groups. Treatment groups were injected with HBsAg-Montanide ISA51VG, the Fendrix and commercial HBsAg-alum, respectively. Montanide ISA51 VG, Alum and PBS injected mice were considered as control groups. Mice were immunized three times with 2-week intervals on days 0, 14 and 28 by subcutaneous injection. Lymphocyte proliferation was assessed with the BrdU method. IFN-γ, IL-2 and IL-4 cytokines, specific total IgG and IgG1/IgG2a isotypes were assessed using ELISA. The HBsAg-Montanide ISA51VG vaccine resulted in a significant increase in lymphocyte proliferation versus HBsAg-alum and higher IL-2 cytokine production versus the Fendrix. Comparable IL-4 and IFN-γ cytokines responses were observed for these vaccines. Following the first immunization, IgG increased more in HBs-Montanide 51VG group versus the HBs-alum group, while after the second and third shots comparable responses were observed in comparison to the HBs-alum group. Monitoring for 220 days after the final vaccination showed the superiority of HBsAg-Montanide ISA 51VG vaccine versus HBsAg-alum and even the Fendrix vaccine in the induction of long-term antibody responses. This study suggests that HBsAg-Montanide ISA51VG as a novel vaccine formulation can trigger both cellular and long-lasting humoral immune responses more efficiently than conventional HBsAg vaccines. © 2021

Related Docs

1. Formulation of Hbs Antigen in Montanide Isa266 Shows Superiority to Commercial Hbsag Vaccine in the Induction of Humoral Immune Responses, Gastroenterology and Hepatology from Bed to Bench (2019)

2. Improvement of Hepatitis B Vaccine to Induce Ifn-Γ Cytokine Response: A New Formulation, Microbial Pathogenesis (2021)

3. Different Formulations of Inactivated Sars-Cov-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses, Viral Immunology (2022)

4. Fast Antibody Responses by Immuno-Targeting and Nanotechnology Strategies Versus Hbsag Vaccine, Iranian Journal of Basic Medical Sciences (2021)

5. Hepatitis B Virus Infection After Immunization: How Serious It Is? an Updated Review, Clinical and Experimental Medicine (2025)

6. Formulation of a Recombinant Hiv-1 Polytope Candidate Vaccine With Naloxone/Alum Mixture: Induction of Multi-Cytokine Responses With a Higher Regulatory Mechanism, APMIS (2021)

7. Killed Whole-Cell Staphylococcus Aureus Formulation in Montanide Isa266 and Alum Adjuvants: Different Vaccine Formulations Varied in the Vaccine’S Potency and Efficacy, Immunologic Research (2025)

Experts (# of related papers)

Seyed Mohammad Jazayeri (1)

Mohammad Hossein Yazdi (1)

Style	Citing Format
MLA	Savoji MA, et al.. "Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses." International Immunopharmacology, vol. 96, no. , 2021, pp. -.
APA	Savoji MA, Sereshgi MMA, Ghahari SMM, Asgarhalvaei F, Mahdavi M (2021). Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses. International Immunopharmacology, 96(), -.
Chicago	Savoji MA, Sereshgi MMA, Ghahari SMM, Asgarhalvaei F, Mahdavi M. "Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses." International Immunopharmacology 96, no. (2021): -.
Harvard	Savoji MA et al. (2021) 'Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses', International Immunopharmacology, 96(), pp. -.
Vancouver	Savoji MA, Sereshgi MMA, Ghahari SMM, Asgarhalvaei F, Mahdavi M. Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses. International Immunopharmacology. 2021;96():-.
BibTex	@article{ author = {Savoji MA and Sereshgi MMA and Ghahari SMM and Asgarhalvaei F and Mahdavi M}, title = {Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses}, journal = {International Immunopharmacology}, volume = {96}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Savoji MA AU - Sereshgi MMA AU - Ghahari SMM AU - Asgarhalvaei F AU - Mahdavi M TI - Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses JO - International Immunopharmacology VL - 96 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract